Patent ID: 6821514
Filing Date: 2004-11-23
Classification: A61K,C12N,C12Y

Abstract:
A composition for reducing symptoms of autism in a human patient comprising a physiologically effective amount of a purified casomorphinase which is a dipeptidyl peptidase, a physiologically effective amount of a purified gluteomorphinase which is a tyrosinase or a phenylalaninase, and at least one of the group consisting of a physiologically acceptable carrier, an adjuvant, an excipient, a buffer and a diluent, wherein the composition is capable of decreasing the incidence of one or more symptoms consisting of eye contact avoidance, failure to socialize, attention deficit, poor mood, hyperactivity, anxiety, stimming, poor comprehension, inappropriate speech, abnormal sound sensitivity, poor digestion, disrupted sleep, and perseveration, and wherein the composition is suitable for oral administration and the decreased incidence is measured relative to the incidence of said one or more symptoms in the untreated individual.